Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.

Journal:

Journal of Clinical Oncology

Published:

2025-07-24

DOI:

10.1200/jco-25-00225

Affiliations:

45

Authors:

32

Go to article

Institutions	Authors	Share
Novartis, Switzerland	4.000000	0.13
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	2.000000	0.06
Medical University of Innsbruck (MUI), Austria	1.000000	0.03
Seoul National University (SNU), South Korea	1.000000	0.03
Fudan University Shanghai Cancer Center (FUSCC), China	1.000000	0.03
Sant'Orsola Malpighi Hospital, Italy	1.000000	0.03
Heidelberg University (Uni Heidelberg), Germany	1.000000	0.03
Novartis Pharmaceuticals Corporation, United States of America (USA)	1.000000	0.03
Ovarian Cancer Research Alliance (OCRA), United States of America (USA)	1.000000	0.03
ARCAGY-GINECO, France	1.000000	0.03
Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Spain	1.000000	0.03
Florida Cancer Specialists and Research Institute (FCS), United States of America (USA)	1.000000	0.03
University of Malaya (UM), Malaysia	1.000000	0.03
São Camilo Oncologia, Brazil	1.000000	0.03
Charité - University Medicine Berlin, Germany	0.500000	0.02
Comenius University in Bratislava (UK), Slovakia	0.500000	0.02
National Oncology Institute of Slovakia, Slovakia	0.500000	0.02
General University Hospital in Prague, Czech Republic	0.500000	0.02
Charles University (CU), Czech Republic	0.500000	0.02
Institute Gustave-Roussy (IGR), France	0.500000	0.02
University Hospitals Leuven (UZ Leuven), Belgium	0.500000	0.02
Nordic Society of Gynaecological Oncology (NSGO), Denmark	0.500000	0.02
Clínica Universidad de Navarra (CUN), UNAV, Spain	0.500000	0.02
Grupo Español de Cáncer de Ovario (GEICO), Spain	0.500000	0.02
Hospital Clinic of Barcelona, Spain	0.500000	0.02
August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Spain	0.500000	0.02
Lyon University Hospital (HCL), France	0.500000	0.02
North-Eastern-German Society of Gynaecologic Oncology (NOGGO e.V.), Germany	0.500000	0.02
Odense University Hospital (OUH), Denmark	0.500000	0.02
Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Belgium	0.500000	0.02
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	0.500000	0.02
Weill Cornell Medicine, United States of America (USA)	0.500000	0.02
Yonsei Cancer Hospital, South Korea	0.500000	0.02
Severance Hospital, Yonsei University, South Korea	0.500000	0.02
Prince of Wales Hospital, Australia	0.500000	0.02
University of New South Wales (UNSW Sydney), Australia	0.500000	0.02
IRCCS Mario Negri Institute, Italy	0.333333	0.01
Agostino Gemelli University Polyclinic, Italy	0.333333	0.01
GTG-UK, United Kingdom (UK)	0.333333	0.01
IRCCS European Institute of Oncology (IEO), Italy	0.333333	0.01
Humanitas University, Italy	0.333333	0.01
Beatson West of Scotland Cancer Centre (BWoSCC), United Kingdom (UK)	0.333333	0.01
University of Glasgow, United Kingdom (UK)	0.333333	0.01
Humanitas San Pio X Hospital, Italy	0.333333	0.01
University of Milano-Bicocca (UNIMIB), Italy	0.333333	0.01

Interested in Oncology and Carcinogenesis?